Carbon monoxide in exhaled breath testing and therapeutics
The EMA directed Novo Nordisk to update product labels to indicate NAION as a rare side effect, defined as occurring in up to 1 in 10,000 users after at least one year of treatment
Tell your provider about all medications you take and your medical history
Abstract Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity
HbA1c reduction was greatest with liraglutide [19,76], and greater with exenatide LAR than with exenatide [17]
Conflict of interest CR has received personal fees from Boehringer Ingelheim, GI Dynamics, Herbalife, Johnson and Johnson, Keyron, Eli Lilly, and Novo Nordisk outside the submitted work